TORONTO and RIONEGRO, Colombia, June 15, 2021 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has made an initial shipment of CBD Isolate (the “Product”) to a Canadian life sciences company that specializes in developing and commercializing proprietary drug-delivery technologies (the “Customer”). The Customer intends to use PharmaCielo’s Active Pharmaceutical Ingredients (APIs) for expanded research and development of their innovative, proprietary sublingual product platform.

PharmaCielo Ltd. Logo (CNW Group/PharmaCielo Ltd.)

PharmaCielo Ltd. Logo (CNW Group/PharmaCielo Ltd.)

“We are very pleased to have partnered with this well-established Canadian life sciences…



Read Full Article Here